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ABSTRACT
Leukotriene B4 (LTB4) is a lipid mediator with potent chemoattractant properties and that is rapidly generated
from activated innate immune cells such as neutrophils, macrophages, and mast cells. Elevated levels of LTB4
have been reported in various allergic diseases and these levels have been related to disease activity and re-
sponse to treatment. Recent studies using LTB4 receptor-1 (BLT1) antagonists or BLT1-deficient mice have re-
vealed that ligation of BLT1 by LTB4 is important for the activation and recruitment of inflammatory cells includ-
ing neutrophils, eosinophils, monocytesmacrophages, mast cells, dendritic cells, and more recently, effector T
cells to inflamed tissues in various inflammatory diseases. The LTB4BLT1 pathway appears to play an impor-
tant role in the pathogenesis of severe persistent asthma, aspirin- and exercise-induced asthma, allergic rhini-
tis, and atopic dermatitis together with other mediators including cysteinyl leukotrienes, cytokines, and
chemokines. LTB4 production is in general resistant to corticosteroid treatment. In fact, corticosteroids can
upregulate BLT1 expression on corticosteroid-resistant inflammatory cells such as neutrophils, monocytes, and
effector memory CD8+ T cells. As a result, this corticosteroid-resistant LTB4BLT1 pathway may contribute to
the development of inflammation in allergic diseases that do not respond to the introduction of corticosteroids.
Inhibition of this pathway has potential therapeutic benefit in various allergic diseases that have involvement of
corticosteroid-insensitivity.
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INTRODUCTION
The leukotrienes (LTs), a family of proinflammatory
lipid mediators, play an important role in the patho-
genesis of allergic inflammation and are divided into
two classes: the chemoattractant LTB4 and the spas-
mogenic cysteinyl LTs [CysLTs: LTC4, LTD4, and
LTE4] also known classically as slow-reacting sub-
stance of anaphylaxis (SRS-A).1-3 These molecules
are generated in leukocytes from membrane arachi-
donic acid through the action of 5-lipoxygenase (5-
LO). LTB4 is rapidly generated from membrane phos-
pholipids of activated innate immune cells by the se-
quential enzymatic actions of cytosolic phospholipase
A2 (cPLA2), 5-LO, and LTA4 hydrolase.1-3 LTB4
serves as a potent chemoattractant through ligation
of the high affinity LTB4 receptor-1 (BLT1) on target
cells.1,2 Various inflammatory diseases, including
asthma,4-9 allergic rhinitis,10-13 atopic dermatitis,14-16
allergic conjunctivitis,17,18 rheumatoid arthritis,19
chronic obstructive pulmonary disease (COPD),20,21
obliterative bronchiolitis after lung transplantation,22
and interstitial lung diseases23,24 are associated with
increased levels of LTB4 andor BLT1 expression and
in some of these diseases LTB4 levels reflect disease
activity and are decreased by treatment.7,12,13,18 Many
studies have shown that LTB4 is not a primary media-
tor of allergic diseases, but may be important in spe-
cific conditions such as severe persistent asthma,25,26
exercise- or aspirin-induced asthma,7,27,28 allergic
rhinitis,10,11 and atopic dermatitis.14-16 Since the 5-LO
pathway is activated in many inflammatory diseases
but is likely resistant to corticosteroid treat-
ment,20,29-34 inhibition of the LTB4-dependent path-
way by modulating either LTB4 synthesis (inhibition
of cPLA2, 5-LO or LTA4 hydrolase), the effects of
LTB4 itself (LTB4 receptor antagonism), or degrada-
tion of LTB4 by peroxisome proliferator-activated re-
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ceptor α (PPARα) activator,35 may have important
benefits in the treatment of these allergic diseases.
BIOSYNTHESIS AND DEGRADATION OF
LTB4
LTB4 is not stored and released but synthesized de
novo from arachidonic acid in activated innate im-
mune cells such as granulocytes, macrophages, and
mast cells following several enzymatic steps.1-3 Ara-
chidonic acid is released from membrane phospholip-
ids by the action of cPLA2 after the activation of cells
by mechanical injury, infection, allergens, cytokines,
or growth factors. Following cellular activation, 5-LO
is translocated to the nuclear membrane and then re-
ceives arachidonic acid donated by the integral nu-
clear membrane protein termed 5-LO-activating pro-
tein (FLAP). 5-LO converts arachidonic acid to 5-
hydroperoxyeicosatetraenoic acid (5-HPETE) and
then the unstable intermediate LTA4. LTA4 is further
metabolized to either LTB4 by LTA4 hydrolase or
CysLTs by LTC4 synthase. Since 5-LO expression is
restricted to myeloid cells while LTA4 hydrolase and
LTC4 synthase are expressed widely, LTs are mainly
produced by leukocytes. Neutrophils produce LTB4
which is strongly chemotactic for leukocytes,
whereas the CysLTs produced by eosinophils in-
crease the contractility of vascular and airway smooth
muscle cells. Monocytesmacrophages are also able
to produce both of these LTs.
LTB4 is inactivated through metabolic degradation
by the microsomal ω-oxidation, mitochondrial and
peroxisomal β-oxidation pathways.1,3 In the ω-
oxidation pathway, LTB4 is converted to 20-hydroxy
LTB4 by LTB4 ω-hydroxylases, which belong to the
cytochrome P450 family 4F3 (CYP4F3) and then to
20-carboxy LTB4 by LTB4 ω-hydroxylases in neutro-
phils or alcohol dehydrogenase and aldehyde dehy-
drogenase in hepatocytes. Two isozymes, CYP4F3A
and CYP4F3B, are expressed in granulocytes and
liver, respectively. Since LTB4 is a hydroxyl fatty acid,
peroxisomal and mitochondrial β-oxidation can be
also involved in the degradation of LTB4. The 12-
hydroxyeicosanoid dehydrogenase expressed ubiqui-
tously can inactivate LTB4 to 12-keto LTB4.
LTB4 RECEPTORS AND SIGNAL TRANS-
DUCTION
Three distinct receptors for LTB4 have been identi-
fied.36-38 The PPARα is the nuclear receptor for ei-
cosanoids including LTB4 and their interaction pro-
motes degradation of lipid mediators.36 PPARα binds
to PPAR responsive elements (PPREs) at the pro-
moter sites of several lipid metabolism-related en-
zymes such as LTB4 ω-hydroxylases (CYP4F3). LTB4
binds and activates PPARα, resulting in the transcrip-
tion of genes that promote fatty acid degradation.
PPARα-deficient mice showed prolonged inflamma-
tory responses in arachidonic acid-induced ear swel-
ling.36 Moreover, PPARα activator can inhibit arachi-
donic acid-induced murine ear inflammation by en-
hancing the degradation of LTB4.35 These data sug-
gest that PPARα plays an important role in the clear-
ance of lipid mediators during inflammation.
Other receptors are cell surface receptors for
LTB4. Both BLT1 and BLT2 are the G protein-
coupled seven transmembrane domain receptors for
LTB4, and their coding genes are located in very
close proximity to each other in the human or mouse
genomes.37,38 These receptors differ in their affinity
and specificity for LTB4 and their expression pattern.
BLT1, a specific high affinity receptor for LTB4, is ex-
pressed predominantly on leukocytes including
granulocytes, monocytesmacrophages, mast cells,
dendritic cells, and effector T cells,37 whereas BLT2,
a low affinity receptor which can also bind to other ei-
cosanoids, is expressed ubiquitously and their bio-
logical role in humans is unknown.38 Mouse BLT2 is
expressed highly in small intestine and skin and a
BLT2-selective agonist induced chemotaxis in pri-
mary mouse keratinocytes and bone marrow mast
cells.39,40 Ligation of BLT1 andor BLT2 by LTB4 trig-
gers a variety of intracellular signal transduction and
cellular events in inflammatory cells, including intra-
cellular Ca2+ mobilization, activation of extracellular
signal-regulated kinase 12, phosphoinositide-3
kinase and Akt, chemotaxis, degranulation, andor
the production of inflammatory proteins.39-42
ASTHMA AND LTB4
Asthma is a complex and heterogeneous chronic dis-
ease characterized by reversible airway obstruction,
allergic airway inflammation, and airway hyperre-
sponsiveness (AHR). LTB4 levels were increased in
the sputum, plasma, and bronchoalveolar lavage
(BAL) fluid of asthmatic patients but not of healthy
subjects.4-6 Increased synthesis of LTB4 was accom-
panied by increased transcriptional upregulation of 5-
LO and LTA4 hydrolase in peripheral blood leuko-
cytes of asthmatic children.43 Generation of LTB4 by
calcium ionophore-stimulated alveolar macrophages
and peripheral blood neutrophils was increased in
asthmatic patients compared to those from healthy
subjects.44 These data suggest that an upregulation of
the LTB4 synthetic pathway in the circulating leuko-
cytes and lungs is associated with asthma.
LTB4 is associated with development of AHR as
well as during an asthma attack. Inhaled meth-
acholine, which is widely used to evaluate AHR,
stimulates LTB4 release in patients with asthma, but
not in healthy subjects, without affecting the number
of inflammatory cells in BAL fluid.45 LTB4 was in-
creased in the arterial blood of asthmatic patients
during wheezing attacks.6 LTB4 levels in BAL fluid
were significantly increased in nocturnal asthma and
correlated with the nocturnal fall in forced expiratory
volume in one second (FEV1). Zileuton (a 5-LO in-
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hibitor) or corticosteroid treatment decreased LTB4
levels and eosinophil numbers in BAL fluid and im-
proved FEV1 in patients with nocturnal asthma.46,47
Zileuton blocked allergic airway inflammation and
AHR in sensitized and challenged animals48 and de-
creased AHR to cold dry air in patients with moderate
asthma,49 suggesting that 5-LO metabolites contrib-
ute to the pathogenesis of asthma. A clinical trial with
the LTB4 antagonist, LY293111, in allergen-induced
asthmatic responses in 12 atopic patients with mild in-
termittent asthma failed to show a therapeutic benefit
except for an inhibitory effect on neutrophil recruit-
ment, but no evidence was presented confirming ac-
tivity in vivo or duration of action.50 LY29311 pre-
vented development of airway hyperresponsiveness
and neutrophil accumulation but failed to inhibit ac-
cumulation of eosinophils in sensitized and chal-
lenged animals.51 However, recent studies using an-
other BLT1 antagonist (CP-105,696) and BLT1-
deficient mice have confirmed the important, if not
essential, role of the LTB4BLT1 pathway in the re-
cruitment of not only neutrophils but also effector T
cells including effector memory CD8+ T cells into the
lungs of allergen-induced allergic airway inflamma-
tory responses in mice.52-58 Inhibition of the LTB4
BLT1 pathway resulted in decreases in airway hyper-
responsiveness and allergic airway inflammation in-
cluding accumulation of eosinophils and lymphocytes
in the airway. Similar to the mouse model of allergic
inflammation, BLT1-expressing effector memory CD8
+ T cells are increased in BAL fluid of human asthmat-
ics.8,9 Although further clinical studies are needed to
evaluate the role of LTB4 in human asthma, the
LTB4BLT1 pathway appears to play an important
role in the pathophysiology of asthma, likely in con-
junction with other mediators including CysLTs, cy-
tokines, and chemokines.
EXERCISE-INDUCED ASTHMA (EIA) AND
LTB4
EIA represents airway narrowing that occurs in asso-
ciation with exercise. Several studies demonstrated a
causal relationship between LTB4 and EIA. Zymosan-
or calcium ionophore-stimulated LTB4 production by
peripheral blood neutrophils was increased after de-
velopment of EIA.59 Recently, it was shown that an-
aerobic exercise-induced stress can enhance the tran-
scription of genes such as ALOX5 and ALOX5AP,
which encode for 5-LO and FLAP in leukocytes and
thus increase plasma LTB4 and LTC4 levels even in
healthy subjects,27 suggesting that LTB4 and CysLTs
may play a role in EIA. Indeed, 5-LO inhibitors have
been shown to attenuate EIA.7 Fish oil-enriched sup-
plements [eicosapentaenoic acid (EPA) and docosa-
hexaenoic acid (DHA)] reduced severity of EIA and
plasma LTB4 and LTE4 levels,60 suggesting fish oil
supplementation may represent a potentially benefi-
cial non-pharmacologic intervention for EIA patients.
ASPIRIN-SENSITIVE ASTHMA (ASA) AND
LTB4
ASA is characterized by the triad of aspirin sensitiv-
ity, severe asthma, severe chronic rhinosinusitis and
recurrent nasal polyposis. ASA is more commonly
found in non-atopic, middle-aged female asthmatic pa-
tients. Increased levels of LTB4 and CysLTs in nasal
polyps have been reported in patients with ASA.61
Furthermore, LTB4 release, but not LTC4, by calcium
ionophore-stimulated peripheral blood monocytes
was increased after oral aspirin challenge and de-
creased after aspirin desensitization in ASA pa-
tients,28 suggesting a key role for LTB4 in the patho-
genesis of ASA. However, other data demonstrated
conflicting results that LTC4 and its receptor CysLT1,
but not the LTB4BLT1 pathway, is involved in the
pathogenesis of aspirin sensitivity62 and anti-CysLTs
agents may be the preferred adjunctive therapy for
ASA.
ALLERGIC RHINITIS AND LTB4
LTB4 is closely related to the pathogenesis of allergic
rhinitis. Specific allergen challenge provokes signifi-
cant increases in nasal airway resistance, numbers of
neutrophils and eosinophils, and levels of protein, his-
tamine, LTB4, and CysLTs in nasal lavage fluid from
patients with allergic rhinitis.10,11 Peripheral blood
neutrophils from patients with allergic rhinitis pro-
duced more LTB4 after calcium ionophore stimula-
tion than healthy subjects.63 Allergen-induced nasal
congestion and increased LTB4 levels in nasal lavage
fluid of patients with allergic rhinitis were signifi-
cantly decreased by treatment with zileuton.12 Selec-
tive histamine receptor H1 antagonists also de-
creased LTB4 levels in nasal fluid from patients with
allergic rhinitis.13 Although the mechanism of action
of currently used antihistamines is primarily through
competitive antagonism of H1 receptors on nerve
endings, smooth muscles, and glandular cells, H1 re-
ceptor antagonism is not likely the sole mechanism of
their action in the treatment of allergic diseases.
Based on in vitro and animal experiments, H1 recep-
tor antagonists also have additional pharmacological
properties such as inhibiting LTs release.64 However,
LTB4 levels in nasal lavage were not changed after
topical corticosteroid treatment even with marked re-
duction in nasal symptoms, levels of histamine, cy-
tokines, and numbers of eosinophils.33,34
ATOPIC DERMATITIS AND LTB4
Atopic dermatitis is a chronic, relapsing allergic skin
disease that affects over 2% of the population. The
pathophysiology of atopic dermatitis is not com-
pletely determined, but immunologic abnormalities
and the subsequent release of inflammatory media-
tors might play a central role. Topical corticosteroids
have been the gold standard of treatment for a long
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time. Many reports demonstrated increased levels of
LTB4 in skin lesions with atopic dermatitis or allergic
contact dermatitis.14-16 Spontaneous and C5a, anti-
IgE, or calcium ionophore-stimulated LTB4 release by
peripheral blood neutrophils was enhanced in pa-
tients with atopic dermatitis.65 The enzymatic activi-
ties of LTA4 hydrolase in peripheral blood leukocytes
were associated with disease severity in patients with
atopic dermatitis and were reduced after improve-
ment of the disease.66 Since increased levels of LTB4
were also demonstrated in other skin diseases such
as psoriasis,14 increases in LTB4 levels do not appear
to be a specific feature of atopic dermatitis. Taken to-
gether, these facts and the biological effects of LTB4
implicate their involvement in the pathogenesis of cu-
taneous inflammation in atopic dermatitis, and may
provide a new target for pharmacological treatment of
this disease.
ALLERGIC CONJUNCTIVITIS AND LTB4
LTB4 causes eosinophil and neutrophil emigration
into conjunctival tissue.67 LTB4 levels were increased
in the tears of patients with seasonal allergic conjunc-
tivitis17 and were decreased by topical treatment with
drugs such as disodium cromoglycate, lodoxamide,
or fluorometholone,18 suggesting a role for LTB4 in
the pathogenesis of allergic conjunctivitis. The role of
LTB4 and its receptor in the pathogenesis of allergic
conjunctivitis and potential benefits of LTB4-specific
antagonists in the treatment of allergic conjunctivitis
remain to be defined.
FISH OIL FATTY ACIDS AND LTB4 IN AL-
LERGIC DISEASES
Fish oils contain 20- and 22-carbon n-3 fatty acid, EPA
and DHA. Since EPA and DHA are incorporated into
cell membranes after dietary intake of fish oils and in-
hibit 5-LO competitively, they can reduce the content
of arachidonic acid and thus suppress conversion of
arachidonic acid to LTB4.68 Furthermore, it has been
recently shown that resolvin E1 (5S, 12R, 18R-
trihydroxyeicosapentaenoic acid), an anti-inflammatory
lipid mediator derived from EPA, binds and blocks
BLT1 and is involved in resolution of allergic inflam-
mation.69 Indeed, ingestion of fish oils changed the
fatty acid composition of neutrophils, decreased LTB4
generation by neutrophils and monocytes, and re-
duced chemotactic activity of neutrophils in asthmatic
patients.70 Moreover, fish oils-enriched supplementa-
tion attenuated allergen-induced late asthmatic re-
sponses in atopic asthma71 and reduced the severity
of EIA and plasma LTB4 levels.60 These findings sug-
gested that fish oil supplementation may represent a
potentially beneficial nonpharmacologic intervention
for LTB4-dependent allergic diseases.
CORTICOSTEROIDS AND THE LTB4BLT1
PATHWAY IN ALLERGIC DISEASES
Corticosteroids effectively suppress inflammatory re-
sponses through repression of many immune genes
by interaction with the glucocorticoid receptor and
are therefore widely used for the treatment of various
allergic diseases. Th2 cytokine-producing CD4+ T
cells and eosinophils play important roles in the
pathogenesis of allergic diseases, and numbers of
these cells, but not CD8+ T cells, were dramatically
decreased in peripheral blood, inflamed bronchial tis-
sues or skin of patients with asthma or atopic derma-
titis after initiation of corticosteroid treatment.72,73
However, it has been shown that a proportion of asth-
matic patients suffered a decline in lung function de-
spite high doses of inhaled or oral corticosteroid
treatment.74 A prospective study has shown a signifi-
cant correlation between annual fall in post-
bronchodilator FEV1 and numbers of peribronchial
CD8+ T cells, but not eosinophils, CD4+ T cells, mast
cells, or subepithelial reticular thickness, in bronchial
biopsies of asthmatic patients treated mostly with in-
haled corticosteroids.75 We identified CD8+BLT1+IL-
13+ T cells in BAL fluid and lung tissues from asth-
matic subjects but not in lung tissue or BAL fluid
from control subjects.9 Paradoxical negative effects of
corticosteroids on neutrophils and monocytes such
as increased LTB4-induced chemotaxis and enhanced
survival through upregulation of BLT1 expression
have been reported.76,77 We recently found that
BLT1-expressing effector memory CD8+ T cells are
more resistant to corticosteroids than CD4+ T cells
and that corticosteroids can enhance the activation
and effector function of this CD8+ T cell subset by
upregulating BLT1 expression through increased IL-
2 receptor expression. This upregulation of BLT1 on
effector memory CD8+ T cells by corticosteroids con-
tributes to their ability to enhance the development of
AHR, allergic airway inflammation, and goblet cell
metaplasia in allergen-sensitized and challenged
mice.42 LTB4 production is itself resistant to corti-
costeroid treatment.20,29-34 Corticosteroid treatment
did not reduce the increased LTB4 levels in serum,
nasal wash fluid, or BAL fluid from patients with
asthma, COPD, or allergic rhinitis,20,30,31 and did not
inhibit calcium ionophore-stimulated release of LTB4
by alveolar macrophages obtained from wheezing in-
fants.32 Furthermore, a neutrophil-activating factor
which augments LTB4 generation by human neutro-
phils was identified in peripheral blood monocytes
isolated from corticosteroid-resistant asthmatics.29 Al-
though some reports showed conflicting results with
decreased in vitro generation of LTB4 by alveolar
macrophages after corticosteroid treatment,31,46 cu-
mulatively these findings suggest that the
corticosteroid-resistant LTB4BLT1CD8+ T cell
pathway may contribute to the pathogenesis of
LTB4 in Allergic Diseases
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Fig. 1 Possible changes in alergic inflammation before and after administration of corticosteroids. Th2 
cytokine-producing CD4＋T cels and eosinophils play an important role in the development of alergic in-
flammation before initiation of corticosteroid treatment. However, numbers of these cels were dramati-
caly decreased in inflamed tissues and blood after administration of corticosteroids. Corticosteroids can 
upregulate BLT1 expression on efector memory CD8＋T cels and neutrophils, but not inhibit production 
of LTB4 from innate immune cels. LTB4 and increased BLT1 expression contribute to the recruitment of 
these cels into inflamed tissues. Corticosteroid-resistant CD8＋T cels, neutrophils, and the LTB4/BLT1 
pathway may play more important roles in corticosteroid-insensitive alergic inflammation after corticoster-
oid administration.
BLT1
Before
After
LTB4 production
Corticosteroid treatment
effector CD8＋T cellseffector CD4＋ T cells eosinophils neutrophils
effector CD8＋T cellseffector CD4＋T cells eosinophils neutrophils
BLT1 upregulation BLT1 upregulation 
LTB4 production
corticosteroid-insensitive allergic inflammation
allergic inflammation
No change in LTB4 levels
activation
activation
migration
migration
apoptosis apoptosis
corticosteroid-insensitive allergic inflammation (Fig.
1).
CONCLUSIONS
Although approximately 30 years have past since
LTB4 was discovered in 1979, recent progress in re-
search using BLT1 antagonists and BLT1-deficient
mice have revealed the important roles of the LTB4
BLT1 pathway in the pathophysiology of various aller-
gic diseases. It is now recognized that corticosteroid
administration in chronic severe persistent allergic
diseases may not be disease-modifying and ineffec-
tive in preventing or reversing the progression of dis-
ease in certain patients. Targeting of the LTB4BLT1
pathway may be an important additive to the treat-
ment of such patients with “corticosteroid-
insensitive” allergic diseases.
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